C.T. Development America, Inc. Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2012)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2012
NCT01215747
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

CT Development America, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

cyclosporine (sandimmune) (1 trial)

eprodisate (Kiacta) (1 trial)

Drugs in Phase 2 Trials (1)

rx-10045 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloidosis (Phase 3)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 2)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3